Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06572267
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-22
Brief Title:
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease a Single-center Triple-blinded Placebo-controlled Exploratory Phase 2 Pilot Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REC-SAFECAD
Brief Summary:
The development of coronary atherosclerosis is closely related to inflammation and CD147 may play an important role in its process The present study was designed to evaluate the effects of long-term administration of mepolizumab humanized anti-CD147 antibody on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease and to preliminarily explore the efficacy safety and dosage of long-term administration of mepolizumab in this population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None